New drug cocktail aims to stall lung cancer

NCT ID NCT07005336

Ongoing Disease control Sponsor: TJ Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a new drug called uliledlimab to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer live longer without their disease getting worse. About 150 adults who have not had prior treatment for their advanced cancer will be randomly assigned to receive either the three-drug combo or the standard two-drug combo. The trial is currently active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: uliledlimab combined with sintilimab and chemotherapy
What this could lead to: If successful, this could lead to a new treatment option that slows the progression of advanced lung cancer.
What could go wrong: This is an early Phase 2 trial with only 150 participants, so results may not apply to everyone. There is also a risk of serious side effects from the combination therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Anhui Provincial Cancer Hospital

Hefei, China
Beijing Chest Hospital

Beijing, China
Binzhou Medical University Hospital

Binzhou, China
Chongqing University Three Gorges Hospital

Chongqing, China
First Hospital of Shanxi Medical University

Taiyuan, China
General Hospital of Ningxia Medical University

Yinchuan, China
Guangxi Medical University Cancer Hospital

Nanning, China
Harbin Medical University Cancer Hospital

Ha’erbin, China
Hubei Cancer Hospital

Wuhan, China
Jiangmen Central Hospital

Jiangmen, China
Linyi People's Hospital

Linyi, China
Lishui Central Hospital

Lishui, China
Shanghai Chest Hospital

Shanghai, China
Shanxi Provincial Cancer Hospital

Taiyuan, China
Sichuan Cancer Hospital

Chengdu, China
The First Affiliated Hospital of Anhui Medical University

Hefei, China
The First Affiliated Hospital of Guangxi Medical University

Nanning, China
The First Affiliated Hospital of Nanchang University

Nanchang, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China
The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, China
The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China
The Second People's Hospital of Neijiang

Neijiang, China
The Second People's Hospital of Yibin

Yibin, China
Xiangyang Central Hospital

Xiangyang, China
Yunan Cancer Hospital

Kunming, China
Zhoukou Central Hospital

Zhoukou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.